A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole.

SAJANI RAMACHANDRAN, RAVICHANDRAN KANDASAMY, KAVITA VERMA, JAYAHSHRI MURUGAN, JISHNU SUDHAKAR, HRIDWIK ADIYERI JANARDHANAN, ANOOP U.R
{"title":"A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole.","authors":"SAJANI RAMACHANDRAN, RAVICHANDRAN KANDASAMY, KAVITA VERMA, JAYAHSHRI MURUGAN, JISHNU SUDHAKAR, HRIDWIK ADIYERI JANARDHANAN, ANOOP U.R","doi":"10.1101/2024.09.11.24313269","DOIUrl":null,"url":null,"abstract":"Aim: To compare the efficacy of a novel maxillofacial drug delivery technology with that of oral administration by analyzing the presence of administered metronidazole in plasma.\nMaterial & Methods:\nThe patients reporting to the Dental outpatient department with acute pulpitis in relation to maxillary molar were examined and recruited for the study. All consenting patients fulfilling the inclusion criteria during the study period were included.\nThe selected patients were randomly divided into two groups using computer generated sequence of random numbers. Group I In the control group patients, a single dose of 400 mg of metronidazole in the form of a tablet was administered through the oral route, after biomechanical preparation of root canals.\nGroup II In the experimental group patients, 5mg of metronidazole in the form of an infusion solution was administered into the pulp cavity of a maxillary molar using the maxillofacial route and technology, after biomechanical preparation of root canals.\nThe blood samples were collected at 15 minutes and 30 minutes after administration of metronidazole. The plasma samples were then analyzed for the presence of metronidazole using high performance liquid chromatography (HPLC).\nResults:\nOut of ten, 5 (50%) samples in the oral route group and all 9 (100%) samples in the maxillofacial route group had the presence of the drug (p = 0.033). There was no statistically significant difference in presence of the drug between 15 minutes and 30 minutes in the oral route (p = 1.0) and in the maxillofacial route (p = 0.687). Further, the mean value of the area under the HPLC curve after 15 minutes was found to be similar in both the groups (p = 0.4). At 30 minutes also the area under the HPLC curve between the groups was not statistically significant (p = 0.156)\nConclusion: The maxillofacial drug delivery technique can be an effective alternate route for painless and controlled drug delivery.","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.11.24313269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To compare the efficacy of a novel maxillofacial drug delivery technology with that of oral administration by analyzing the presence of administered metronidazole in plasma. Material & Methods: The patients reporting to the Dental outpatient department with acute pulpitis in relation to maxillary molar were examined and recruited for the study. All consenting patients fulfilling the inclusion criteria during the study period were included. The selected patients were randomly divided into two groups using computer generated sequence of random numbers. Group I In the control group patients, a single dose of 400 mg of metronidazole in the form of a tablet was administered through the oral route, after biomechanical preparation of root canals. Group II In the experimental group patients, 5mg of metronidazole in the form of an infusion solution was administered into the pulp cavity of a maxillary molar using the maxillofacial route and technology, after biomechanical preparation of root canals. The blood samples were collected at 15 minutes and 30 minutes after administration of metronidazole. The plasma samples were then analyzed for the presence of metronidazole using high performance liquid chromatography (HPLC). Results: Out of ten, 5 (50%) samples in the oral route group and all 9 (100%) samples in the maxillofacial route group had the presence of the drug (p = 0.033). There was no statistically significant difference in presence of the drug between 15 minutes and 30 minutes in the oral route (p = 1.0) and in the maxillofacial route (p = 0.687). Further, the mean value of the area under the HPLC curve after 15 minutes was found to be similar in both the groups (p = 0.4). At 30 minutes also the area under the HPLC curve between the groups was not statistically significant (p = 0.156) Conclusion: The maxillofacial drug delivery technique can be an effective alternate route for painless and controlled drug delivery.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于给药的新型颌面技术--使用甲硝唑的随机对照试验
目的:通过分析血浆中甲硝唑的含量,比较新型颌面部给药技术与口服给药技术的疗效。利用计算机生成的随机数字序列将所选患者随机分为两组。对照组患者在进行根管生物力学准备后,通过口服途径服用单剂量 400 毫克片剂甲硝唑。实验组患者在进行根管生物力学准备后,通过颌面部途径和技术将 5 毫克输液形式的甲硝唑注入上颌磨牙的牙髓腔。结果:在 10 份样本中,口服途径组有 5 份样本(50%)含有甲硝唑,颌面途径组有 9 份样本(100%)含有甲硝唑(P = 0.033)。在 15 分钟和 30 分钟之间,口服途径(p = 1.0)和颌面途径(p = 0.687)的药物含量没有明显的统计学差异。此外,两组 15 分钟后的 HPLC 曲线下面积的平均值相似(p = 0.4)。30 分钟后,两组的 HPLC 曲线下面积也没有统计学意义(p = 0.156):颌面部给药技术是无痛、可控给药的有效替代途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tucaresol: An Oral Candidate Drug With Two Distinct Antiviral Mechanisms. Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3–Acid-Ethyl-Esters Adjuvant to Statins A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole. Protective Effects of Psychiatric Medications against COVID-19 Mortality Before Vaccines Anti-cancer effect of memantine as adjunctive therapy in metastatic colon cancer: A pilot randomized controlled clinical trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1